Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation

Inclusion Criteria: * Informed consent as documented by signature * Severe AS and scheduled for transfemoral TAVI Exclusion Criteria: * Contraindications to the class of drugs under study (C1INH), e.g., known hypersensitivity or allergy to class of drugs or the investigational product * History of allergy to rabbits (as rhC1INH is derived from the breast milk of transgenic rabbits) * Women who are pregnant or breast feeding * Hemodynamic instability requiring emergency TAVI * Valve-in-valve procedure * Other access route than transfemoral * Non-cardiac co-morbidity with expected survival \<6 months * Ischemic or hemorrhagic stroke within 30 days before TAVI * Dialysis or estimated glomerular filtration rate (eGFR) \<20 ml/min/1.73m2 * Contraindication for MRI such as a permanent non-MRI compatible pacemaker or severe claustrophobia * Liver cirrhosis (any Child-Pugh score) * Incapacity or inability to provide informed consent * Participation in another study with investigational drug or medical device within the 30 days preceding and during the present study * Previous enrolment into the current study * Any uncontrolled or significant concurrent illness that would put the patient at a greater risk or limit compliance with the study requirements at the discretion of the investigator